Effects of GSK1070806 (anti-IL18 mAb) on biomarkers in synovial tissue and blood of patients with rheumatoid arthritis.

尽管近年来新疗法的引入极大地改善了类风湿性关节炎患者的前景，但仍有相当多的需求未得到满足。这项工作将评估一种潜在的新的作用模式，可用于早期或建立类风湿关节炎，以阻止疾病的进展。我们将评估由GSK 1070806诱导的滑膜组织（关节周围的膜，关节炎的炎症靶点）中观察到的炎症变化，GSK 1070806是一种靶向关节中炎症信使的新药。将在3个中心招募13例患者。我们的探索性目标是研究通过一系列尖端方法评估的滑膜炎症的变化。还将评估安全性和耐受性。

Although the introduction of novel therapies has greatly improved the outlook for patients with rheumatoid arthritis over the years, considerable unmet needs remain. This work will evaluate a potential new mode of action that could be used in early or established rheumatoid arthritis to halt the progression of disease. We will evaluate changes in inflammation observed in the synovial tissue (the membrane around the joint, target of inflammation in arthritis) induced by GSK1070806, a new drug targeting a messenger of inflammation present in the joint. 13 patients will be recruited across 3 centers. Our exploratory objectives will study changes in synovial inflammation evaluated by a range of cutting edge methodologies. Safety and tolerance will also be assessed.